Search

Search Results
Results 11691 - 11700 of 13351 for Abnormal
  • Topamax
    Drug - 3 Mar 2026
    Consumer Medicine Information (CMI) about Topamax intended for persons living in Australia.
  • Omjjara
    Drug - 13 Feb 2026
    Consumer Medicine Information (CMI) about Omjjara intended for persons living in Australia.
  • Tracing the decline in American heart disease mortality
    News - 21 Jan 2026
    Following a five-year upward trend likely impacted by the COVID pandemic, the number of heart disease and stroke deaths has declined, yet, heart disease and stroke still kill more people in the U.S....
  • The shift toward multi-target strategies in obesity therapeutics
    White Paper - 20 Jan 2026
    A deep dive into the scientific shift toward multi-target obesity therapeutics and its implications for metabolic health and disease prevention.
  • Sublocade
    Drug - 16 Jan 2026
    Consumer Medicine Information (CMI) about Sublocade intended for persons living in Australia.
  • Syquet
    Drug - 5 Jan 2026
    Consumer Medicine Information (CMI) about Syquet intended for persons living in Australia.
  • Opdivo SC
    Drug - 19 Dec 2025
    Consumer Medicine Information (CMI) about Opdivo SC intended for persons living in Australia.
  • Opdivo
    Drug - 16 Dec 2025
    Consumer Medicine Information (CMI) about Opdivo intended for persons living in Australia.
  • Reagila
    Drug - 15 Dec 2025
    Consumer Medicine Information (CMI) about Reagila intended for persons living in Australia.
  • Dapa-Tabs
    Drug - 10 Dec 2025
    Consumer Medicine Information (CMI) about Dapa-Tabs intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback